Neurocrine Bio. (NBIX) PT Raised to $115 at BMO Capital as 'Crenessity Surprises Higher'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $115.00 (from $96.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
